Financial terms were not disclosed, although Nordion will leave an estimated US$18m in the company.
Best Medical has acquired all of MDS Nordion, with the exception of the TheraSphere business, which develops liver cancer therapeutics.
The firm bought another Nordion company, Ottawa-based Theratronics, four years ago.
Nordion made a decision in the 2010 financial year to restructure or exit this business, stating that it wanted to reduce complexity, manage costs and focus on growing areas of the business.
The 55 employees at MDS Nordion will transfer to Best Medical, which will also acquire the Belgian production facilities.
Nordion expects the transaction to be completed in the next few months.
Nordion sells Belgian operation
Best Medical to buy MDS Nordion, terms not revealed
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
Upcoming event
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities
The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
Finance
Applied Biopharm Consulting secures IP grant to protect AI-driven viral capsid engineering innovations
Irish biotech consultancy Applied Biopharm Consulting has received an IP Start Grant from Enterprise Ireland to develop a formal patent strategy around its AI-powered computational platform for engineered adeno-associated virus vector design
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
kyron.bio partners with Servier to advance precision glycosylation in antibody therapeutics
The parternship will allow kyron.bio to apply its precision glycoengineering platform to antibody development. Speaking exclusively with Manufacturing Chemist, CEO of kyron.bio, Dr Emilia McLaughlin, explains the importance of the new deal